Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $29.37 USD
Change Today +0.63 / 2.19%
Volume 102.8K
GKOS On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

glaukos corp (GKOS) Snapshot

Open
$28.92
Previous Close
$28.74
Day High
$29.61
Day Low
$28.26
52 Week High
08/19/15 - $33.92
52 Week Low
07/2/15 - $27.04
Market Cap
940.3M
Average Volume 10 Days
137.7K
EPS TTM
--
Shares Outstanding
32.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GLAUKOS CORP (GKOS)

Related News

No related news articles were found.

glaukos corp (GKOS) Related Businessweek News

No Related Businessweek News Found

glaukos corp (GKOS) Details

Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline comprises iStent Inject Trabecular Micro-Bypass Stent, which allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving greater intraocular pressure reduction; iStent Supra Suprachoroidal Micro-Bypass Stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small-gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products directly in the United States and Germany; and through distribution partners in Europe, the Asia Pacific, Canada, and internationally. The company was founded in 1998 and is headquartered in Laguna Hills, California.

120 Employees
Last Reported Date: 06/25/15
Founded in 1998

glaukos corp (GKOS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $720.5K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $337.2K
Chief Commercial Officer
Total Annual Compensation: $394.4K
Compensation as of Fiscal Year 2014.

glaukos corp (GKOS) Key Developments

Glaukos Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Glaukos Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's net sales were $11,099,000 compared to $17,754,000 a year ago. Loss from operations was $2,244,000 compared to $5,382,000 a year ago. The growth was driven by increased adoption of the company’s iStent Trabecular Micro-Bypass Stent. Loss before taxes was $2,494,000 compared to $32,512,000 a year ago. Net loss was $2,494,000 compared to $32,512,000 a year ago. Net loss attributable to the company was $2,074,000 compared to $31,928,000 a year ago. Net loss per share, basic and diluted, attributable to the company common stockholders was $0.90 compared to $10.96 a year ago. Weighted average shares used to compute pro forma basic and diluted net loss per share attributable to the company common stockholders was $23,920,000 compared to $24,558,000 a year ago. Pro forma net loss per share, basic and diluted unaudited, attributable to the company common stockholders was $0.09 compared to $1.30 a year ago. For the six months, the company's net sales were $19,348,000 compared to $32,420,000 a year ago. Loss from operations was $6,270,000 compared to $6,566,000 a year ago. Loss before taxes was $6,831,000 compared to $33,974,000 a year ago. Net loss was $6,833,000 compared to $33,974,000 a year ago. Net loss attributable to the company was $6,031,000 compared to $32,894,000 a year ago. Net loss per share, basic and diluted, attributable to the company common stockholders was $2.70 compared to $12.35 a year ago. Weighted average shares used to compute pro forma basic and diluted net loss per share attributable to the company common stockholders was $23,846,000 compared to $24,307,000 a year ago. Pro forma net loss per share, basic and diluted unaudited, attributable to the company common stockholders was $0.25 compared to $1.35 a year ago.

Health Canada Approves the Glaukos iStent inject®

Glaukos Corporation announced that Health Canada has approved its iStent inject® Trabecular Micro-Bypass Stent for the reduction of intraocular pressure (IOP) in patients diagnosed with primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma. With this approval, the iStent inject can be used in combination with cataract surgery in patients who require IOP reduction and/or would benefit from glaucoma medication reduction. iStent inject is also indicated as a standalone procedure for patients who continue to have elevated IOP despite prior treatment with glaucoma medications or conventional glaucoma surgery.

Glaukos Corporation Announces Completion of Patient Enrollment in U.S. Pivotal Clinical Trial for iStent inject®

Glaukos Corporation announced the completion of patient enrollment in its U.S. Food and Drug Administration (FDA) pivotal Investigational Device Exemption (IDE) trial for the iStent inject® Trabecular Micro-Bypass Stent. The iStent inject relies on a similar fluidic method of action as the company’s iStent® Trabecular Micro-Bypass Stent, which was approved by the FDA in 2012 and has been shown to lower intraocular pressure in adult cataract patients with mild-to-moderate open-angle glaucoma. The iStent inject is comprised of a micro-needle that is preloaded with two stents and driven by an auto-inject mechanism for predictable and facile implantation. The iStent inject is designed to enable ophthalmic surgeons to inject stents into multiple trabecular meshwork locations through a single corneal entry point. The iStent inject is approximately one-third the size of iStent, which Glaukos believes is the smallest device ever approved by the FDA. The iStent inject prospective, randomized, multicenter clinical trial includes approximately 40 sites and 500 randomized subjects. Subjects in the trial are randomized to either iStent inject in combination with cataract surgery or cataract surgery alone. The study protocol calls for randomized subjects to be followed for two years, with a primary endpoint of a 20% or greater reduction in intraocular pressure from baseline. The results of the trial are expected to form the basis for the company’s future Pre-Market Approval (PMA) submission to the FDA. The iStent inject is already approved for commercial use in the European Union and Australia, and Glaukos is currently conducting an initial commercial launch of iStent inject in Germany. In addition to conducting an iStent inject U.S. IDE pivotal trial in combined cataract procedures, Glaukos is also conducting an initial U.S. IDE clinical trial to evaluate a second version of the iStent inject to be used as a standalone procedure in glaucoma patients who are not undergoing concurrent cataract surgery. The objective of this version of the iStent inject is to make micro-scale injectable therapy a viable option for a much larger segment of the patient population with open-angle glaucoma.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GKOS:US $29.37 USD +0.63

GKOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ellex Medical Lasers Ltd A$0.38 AUD -0.005
Lumenis Ltd $13.90 USD -0.01
STAAR Surgical Co $7.99 USD -0.10
View Industry Companies
 

Industry Analysis

GKOS

Industry Average

Valuation GKOS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 9.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAUKOS CORP, please visit www.glaukos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.